Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

cure me

Needle Exchange Programs Needed To Prevent Spread Of HIV, Letter To The Editor Says
"Despite making strides in addressing HIV/AIDS, we have not reached all individuals and communities with the full range of prevention tools needed to reverse the epidemic," Jirair Ratevosian, chair of the American Public Health Association International Health Section"s Advocacy and Policy Committee, writes in a Washington Post letter to the editor. Ratevosian continues, "Congress has a chance to help by lifting the ban on federal funding for syringe exchange programs," adding, "Such programs do more than just distribute clean syringes; they link people into the health care system and drug treatment programs." Ratevosian also discussed support of needle exchange programs by several national health organizations and concludes, "It is imperative that effective approaches to preventing HIV be accessible without delay" (Ratevosian, 7/24).
Polygraphy
Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
Boston Scientific Corporation (NYSE: BSX) announced the launch of the platinum chromium TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System in select markets worldwide. The TAXUS Element Stent features a new platinum chromium alloy engineered specifically for coronary stent applications and represents the Company"s third-generation drug-eluting stent (DES) technology.
News of the day
Gefitinib Receives European Licence For The Treatment Of Lung Cancer For Patients With EGFR Activating Mutation Positive Tumours
AstraZeneca announced that it has received a licence by the European Medicines Agency (EMEA) for its oral targeted anti-cancer drug, gefitinib, for EGFR (epidermal growth factor receptor-tyrosine kinase) activating mutation positive patients with Non Small Cell Lung Cancer (NSCLC). NSCLC is the most common type of lung cancer and accounts for 80% of all lung cancer cases. [1] The licence means that for the first time, thousands [2] of patients undergoing first line treatment of NSCLC in the UK may benefit from a more effective, [3] oral alternative to doublet chemotherapy (UK standard of care) without many of the side effects associated with chemotherapy. [3]
Nutrition

Medical Expulsive Therapy As An Adjunct To Improve Shockwave Lithotripsy Outcomes: A Systematic Review And Meta-Analysis

UroToday.com - Over the past decade, the most significant advance, in my mind, with regard to the treatment of the distal ureteral stone, has been the advent of medical expulsive therapy as described by Porpiglia and colleagues in 2000, and corroborated by many subsequent studies. Savings with this approach, according to work by Lotan and colleagues, is around $1100/patient in addition to the benefits of decreased renal colic. Stone passage rates increase anywhere from 40-100% of controls within 10 days of starting medical expulsive therapy. While a variety of medications have been used (e.g. alpha blockers, steroids, calcium channel blockers), the alpha blockers (i.e. tamsulosin and alfuzosin) appear to be effective and well tolerated. Is medical expulsive therapy worthwhile in the post SWL patient who has multiple stone fragments to pass? The answer appears to be: YES. In this meta-analysis of four randomized trials, the authors noted a 17% absolute increase in stone free rates (i.e. UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009